VYNE Therapeutics Inc. (NASDAQ:VYNE – Get Rating) was the target of a significant decline in short interest in May. As of May 15th, there was short interest totalling 91,900 shares, a decline of 55.6% from the April 30th total of 206,800 shares. Currently, 2.9% of the shares of the company are sold short. Based on […]
VYNE Therapeutics (NASDAQ:VYNE – Get Rating) had its price target lifted by Cantor Fitzgerald from $5.00 to $9.00 in a report released on Friday morning, The Fly reports. Separately, HC Wainwright reaffirmed a buy rating and set a $28.00 target price on shares of VYNE Therapeutics in a report on Wednesday, April 19th. VYNE Therapeutics […]
VYNE Therapeutics Inc. (NASDAQ:VYNE – Get Rating) was the recipient of a large increase in short interest in April. As of April 30th, there was short interest totalling 206,800 shares, an increase of 119.1% from the April 15th total of 94,400 shares. Based on an average daily volume of 694,700 shares, the days-to-cover ratio is […]
VYNE Therapeutics Inc. (NASDAQ:VYNE – Get Rating) was the target of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 98,200 shares, an increase of 30.2% from the March 15th total of 75,400 shares. Based on an average daily volume of 57,200 shares, the […]
29.03.2023 - Generated record total revenues of $73.7 million for the full year 2022 Completed enrollment in Phase 3 clinical program evaluating DFD-29 for the treatment of papulopustular rosacea; topline data are expected in the first half of 2023 Company to .